Drug

Exemestane (Aromasin)

An aromatase inhibitor tablet for hormone receptor-positive breast cancer in women after menopause

Updated: 27 October 20261 min read4 references
Generic name
Exemestane
Brand names
Aromasin
Drug class
Steroidal aromatase inhibitor
Route
Oral (tablet)
Show content for:

Key points

  • Exemestane is a 25 mg tablet taken once a day after a meal [1].
  • It lowers oestrogen production in women after menopause so that hormone receptor-positive breast cancer does not come back or grow [1].
  • In younger women it is used together with a drug that switches off the ovaries [3].
  • It puts a strain on the bones; bone density scans, calcium and vitamin D are needed.

What is this drug and how does it work?

For patients

After menopause, most oestrogen is made in fat tissue by an enzyme called aromatase. Exemestane switches this enzyme off permanently [1].

For physiciansSpecialist notes
For physicians

An irreversible, steroidal aromatase inhibitor (type 1 inactivator) [1].

Which cancers is it used for?

For patients
What is this drug for?
  • Adjuvant treatment of hormone receptor-positive breast cancer in women after menopause (from the start or after 2 to 3 years of tamoxifen) [1, 2]
  • With ovarian suppression in high-risk premenopausal women [3]
  • Advanced breast cancer, alone or with everolimus [1, 4]
For physiciansApproved uses and evidence
For physicians
Approved uses and evidence
DiseaseUseKey evidence
Early breast cancer, after 2 to 3 years of tamoxifenSwitch to exemestaneIES: longer disease-free survival than continuing tamoxifen [2]
Premenopausal, high riskWith ovarian suppressionSOFT/TEXT: fewer recurrences than tamoxifen with ovarian suppression [3]
Advanced, after a non-steroidal inhibitorWith everolimusBOLERO-2: longer progression-free survival [4]

How it is taken and dosing

Show detailsHide

One 25 mg tablet a day, after a meal [1]. It usually continues for 5 years (sometimes longer).

For physiciansStandard dosing (FDA label), 1 regimen
For physicians

Standard dosing (FDA label)

Exemestane

HR+ breast cancer in postmenopausal womenCycle length: Daily

HR+‎ breast cancer in postmenopausal women

DrugDoseRouteSchedule
Exemestane25 mg once dailyOral, after a mealDaily
Cycle length
Daily
Duration
Adjuvant: 5 years of endocrine therapy in total (or longer); advanced: until progression

With a strong CYP3A4 inducer (rifampicin, phenytoin): 50 mg once daily [1]. In premenopausal women, only with ovarian suppression [3].

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Side effects

For patients

The most common side effects: hot flushes, tiredness, joint pain, headache, trouble sleeping and sweating [1].

For physiciansSpecialist notes
For physicians

Hot flushes, fatigue, arthralgia, headache, insomnia, sweating; decreased bone mineral density and raised cholesterol [1].

Serious side effects

For patients

Less common serious side effects: loss of bone density and fractures [1].

For physiciansSpecialist notes
For physicians
  • Bone density: baseline and periodic measurement; calcium, vitamin D and a bone-protective drug if needed (bone health lesson).
  • Not effective in premenopausal women without ovarian suppression [1].

When should I call my doctor?

  • Bone pain or a fracture after a minor knock
  • Severe joint pain that disrupts daily activities
  • Unusual bleeding

Interactions, pregnancy and precautions

  • Other medicines: do not take oestrogen-containing products with it; rifampicin and epilepsy medicines reduce its effect [1].
  • Pregnancy: this drug may harm an unborn baby; use effective contraception during treatment and tell your doctor straight away if you become pregnant. Do not breastfeed during treatment [1].
For patients

Frequently asked questions

What can I do about joint pain?

Regular exercise and simple painkillers help; if it is severe, talk to your doctor about another drug and do not stop on your own.

Related cancer types

References

4 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    AROMASIN (EXEMESTANE) — Prescribing InformationPhysicians Total Care, Inc · FDA label · 2026
    Source Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
  2. 2
    A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerCoombes RC, Hall E, Gibson LJ, et al · N Engl J Med · 2004;350:1081-92
    DOIPubMed Back to text: 1 2
  3. 3
    Adjuvant exemestane with ovarian suppression in premenopausal breast cancerPagani O, Regan MM, Walley BA, et al · N Engl J Med · 2014;371:107-18
    DOIPubMed Back to text: 1 2 3 4
  4. 4
    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerBaselga J, Campone M, Piccart M, et al · N Engl J Med · 2012;366:520-9
    Study cardDOIPubMed Back to text: 1 2

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.